Università degli Studi di Padova

Padua Research Archive - Institutional Repository

Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinoma

Original Citation:

Availability:

This version is available at: 11577/3260651 since: 2018-03-18T13:26:24Z

Publisher:

Springer Berlin

Published version:

DOI: 10.1007/s00259-015-3266-4

Terms of use:

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)

Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinoma

Fabio Zattoni^{1,2} • Laura Evangelista³ • Andrea Guttilla¹ • Filiberto Zattoni¹

Received: 10 November 2015 / Accepted: 19 November 2015
© Springer-Verlag Berlin Heidelberg 2015

Sir,

We read with great interest the paper by Sassa et al. published in the *European Journal of Nuclear Medicine and Molecular Imaging* entitled “Evaluation of ¹¹C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: a pilot study” [1]. Nuclear medicine modalities are able to detect metabolic changes in neoplastic cells. This has been demonstrated in many tumours, but the role of FDG and ¹¹C-choline PET/CT in the evaluation of upper urinary tract urothelial carcinoma (UUT-UC) is still undefined. Thus, we are grateful to the authors for the interesting and innovative study. To date, few data are available regarding the staging of UUT-UC, and unfortunately the level of evidence is poor, especially for lymph node evaluation.

Sassa et al. [1] in their prospective study enrolling 16 patients found a sensitivity and specificity in lymph node invasion of 91.6 % and 50 %, respectively. Conversely, Asai et al. [2] in their retrospective study in 50 patients found a sensitivity and specificity of 83 % and 100 %, respectively, using FDG as a metabolic radiopharmaceutical agent. Beyond the limitations of these studies, it is reasonable to imagine that PET/CT could play a role in the staging of UUT-UC and in planning lymph node dissection (LND). The best LND

template is still unknown and it is limited to staging only [3]. However, some limitations and controversies have arisen. Firstly, LND in transitional cancer of the bladder is used for both tumour staging and cancer control. This is in contrast to what is known on UUT-UC, even though UUT-UC has the same histotype of the lower urinary tract. Secondly, CT urography has the highest diagnostic accuracy in UUT-UC [4–6], but its performance in detecting suspicious lymph node metastases has not been fully evaluated. Although the presence of enlarged lymph nodes is highly predictive of metastasis [7], the anatomical site for the LND has not been clearly defined and consequently the effective accuracy of imaging is doubtful. Thirdly, few models that are able to accurately predict lymph node involvement in locally advanced cancer have been described [8]. Fourthly, it seems that the number of removed lymph nodes has a lower impact on patient survival than the LND template [9]. Lastly, CT urography and MRI are unable to discriminate patients with a high risk of lymph node metastases from those with a low/intermediate risk, and thus are unable to guide LND planning.

The promising results of ¹¹C-choline PET/CT in the primary diagnosis and staging of UUT-UC raises interesting questions that only further studies will answer:

1. Can we use radiolabelled choline PET/CT to better stratify patients and to understand the best LND template?
2. Can PET/CT change the indication to conservative surgery (endourological treatment) from more aggressive surgery (nephroureterectomy with lymphadenectomy)?
3. Do coregistration of CT urography and PET/CT data allow better staging of primary tumour and lymph node metastases?

Moreover, Asai et al. [2] found that using a dedicated protocol for patient preparation, hypermetabolic lesions could be

✉ Fabio Zattoni
fabiozattoni@gmail.com

¹ Department of Oncological and Surgical Sciences, Urology Clinic University of Padua, Padua, Italy

² Clinical and experimental Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology University of Padua, Padua, Italy

³ Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV IRCCS, Padua, Italy

easily detected and UUT-UC precisely located by FDG PET/CT in spite of the difficulties posed by urinary excretion of the tracer. Therefore, FDG PET/CT could be considered an alternative diagnostic strategy in this setting.

In conclusion, we believe that Sassa et al. [1] have raised more questions than answers. Further studies are needed in this tumour that is close to bladder cancer but at the same time completely different and unclear.

References

1. Sassa N, Kato K, Abe S, Iwano S, Ito S, Ikeda M, et al. Evaluation of ¹¹C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: a pilot study. *Eur J Nucl Med Mol Imaging*. 2014;41:2232–41.
2. Asai S, Fukumoto T, Tanji N, Miura N, Miyagawa M, Nishimura K, et al. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma. *Int J Clin Oncol*. 2015;20:1042–7.
3. Rouprêt M, Nabjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. *Eur Urol*. 2013;63:1059–71.
4. Fritz GA, Schoellnast H, Deutschmann HA, Quehenberger F, Tillich M. Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. *Eur Radiol*. 2006;16:1244–52.
5. Maheshwari E, O'Malley ME, Ghai S, Staunton M, Massey C. Split-bolus MDCT urography: upper tract opacification and performance for upper tract tumors in patients with hematuria. *AJR Am J Roentgenol*. 2010;194:453–8.
6. Sudakoff GS, Dunn DP, Guralnick ML, Hellman RS, Eastwood D, See WA. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. *J Urol*. 2008;179:862–7.
7. Millán-Rodríguez F, Palou J, de la Torre-Holguera P, Vayreda-Martija JM, Villavicencio-Mavrich H, Vicente-Rodríguez J. Conventional CT signs in staging transitional cell tumors of the upper urinary tract. *Eur Urol*. 1999;35:318–22.
8. Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. *J Urol*. 2013;189:1662–9.
9. Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H, Ito F, et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. *Int J Urol*. 2010;17:848–54.